Twitter

Chordate Medical’s CEO to attend investor conference in Switzerland

Chordate Medical’s CEO, Anders Weilandt, will present Ozilia at Swiss Nordic Bio in Zurich on March 7th. Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting Nordic and Swiss startups in the Life Science sector with investors and industry partners.

“As we continue to penetrate key markets, we will increasingly focus on raising awareness about the company and Ozilia within the industrial and investor circles surrounding Life Science. Swiss Nordic Bio is one of several important forums in this context during the spring where we participate to present Ozilia’s potential,” said Anders Weilandt, CEO of Chordate.

Swiss Nordic Bio has been held for 17 years and was previously known as the Swiss Scandinavian Bio-Business Seminar. The conference is hosted by Vator Securities and Business Sweden and organized together with stakeholders from the Nordic countries in collaboration with Swiss partners.

“The conference focuses on biotechnology, medtech, and the pharmaceutical industry. In addition to development companies like Chordate and investors, global companies from these three fields also participate, making this the perfect forum for us to be a part of.”

Read more about Swiss Nordic Bio

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter